View more job listings or post a job
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Post a job


[Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6

Speakers: Philippe Calais, MatriSys; Ping Cao, BridGene; Johannes Hermann, Frontier Medicines; Heather Webb Hsu, Inipharm; Shengjiang (Shawn) Liu, Avirmax; Matthew Meyer, Life Sciences at Wilson Sonsini Goodrich & Rosati.
Organizers: Toby Freedman (Synapsis Search); Sarah Bodary (AbCellera); Donald McCarthy (Samsara BioCapital); Shichang Miao (PBSS), Lu Lu (MicuRx Pharmaceuticals, Inc.)
Date: 2024-07-24
Time: 8:30-13:00 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2024-07-23  (it will close sooner if the seating cap is reached)

About the Topic

This symposium series aims to provide a platform for promising biotech startup companies to highlight their science and share their stories in building a fledgling business.

Time (PT) Topic Speaker
8:30-8:40 am PBSS Welcome Shichang Miao, PhD, PBSS
8:40-9:15 am The Final Frontier: Removing the “Un” from Undruggable Johannes Hermann, PhD, CTO, Frontier Medicines
9:15-9:50 am Live Biotherapeutics to Transform the Treatment of Skin Diseases Philippe Calais, PharmD, PhD, CEO, MatriSys Bioscience
9:50-10:25 am Targeting Chronic Liver Disease Through Genetic Insights Heather Webb Hsu, PhD, CSO, Inipharm
10:25-10:35 am Break -
10:35-11:10 am Unlocking the Proteome: Novel Covalent Drug Discovery Strategies for Targeting Hard-To-Drug Targets Through Chemoproteomic Platform IMTAC Ping Cao, PhD, CEO, BridGene Biosciences
11:10-11:45 am My Passion to Vision Preservation Shengjiang (Shawn) Liu, PhD, CEO/CSO, Avirmax
11:45-12:20 pm Best Practices When Pitching to Venture Investors Matthew Meyer, JD, Chief Business Advisor, Life Sciences at Wilson Sonsini Goodrich & Rosati
12:20-12:55 pm Panel Discussion, Q&A and Symposium Conclusion All Speakers

About the Speakers

-- Philippe Calais, the President and Chief Executive Officer of MatriSys Bioscience, has 37 years of  experience managing across all functions of the drug development chain from discovery  through commercialization, partnership, fund raising and IPOs. Philippe is also the founder and  the executive chairman of the board of Phileas Pharma, developing a gene therapy for a rare  children ophthalmology disease. Philippe also serves as the executive chairman of the board of  clinical stage oncology Transcode Therapeutics (Nasdaq: RNAZ). In addition, Philippe teaches  clinical development for graduate students as a Research Associate Professor in the Center for  Molecular Biology & Biotechnology in the Charles E. Schmidt College of Science at Florida  Atlantic University (FAU) and is a member of the FAU amyloid task force.  Prior to joining MatriSys, Philippe served as Director and Interim Chief Executive Officer of  CohBar (Nasdaq: CWBR) .

He has more than 24 years of experience in North America and 13 years in Europe managing  specialty and biotech both privately held and publicly traded (Nasdaq, OTCQB, TSX, CNSX)  companies in broad therapeutic spaces including oncology, anti-infectives, cardiovascular, CNS and the microbiome. He also served as head of global strategic marketing for anti-infectives at  Hofmann-La Roche.

Philippe holds a Bachelor’s degree in Pharmacy and a Doctorate in Pharmacy from the  University François-Rabelais in Tours, France.

-- Heather Kay Webb Hsu is the Chief Scientific Officer for Inipharm, a company focused on drugs targeting genetically-defined mechanisms for the treatment of chronic liver disease and metabolism.  Heather Hsu has over 25 years of pharmaceutical/biotech industry experience with research and development. Her PhD in Biological Chemistry from the University of Michigan included a collaboration with Eli Lilly.  In the years since, Heather has led pharmacology and nonclinical research teams in indication areas including, oncology, cardiometabolic and liver diseases at companies including Johnson and Johnson and Gilead Sciences as well as Calistoga Pharmaceuticals.

--Matthew J. Meyer is the chief business advisor in the life sciences practice of Wilson Sonsini Goodrich &  Rosati. Based in San Francisco, Matthew leads the firm's life science business advisory practice—an innovative resource aimed at providing start-up and emerging growth stage life sciences companies with  business insights, strategy, capabilities, and transactional support related to financings, company set-up,  growth, commercialization, partnerships, and M&A transactions. 

Matthew is an experienced, high-impact business executive and corporate attorney who has held  diverse roles of increasing responsibility across a wide range of private and public biopharma, digital  health, and precision medicine companies from start-ups to Fortune 50 corporations in the U.S. and  Europe, including Pfizer, Novartis, Myriad Genetics and CareDx. His leadership capabilities include  delivery of strong commercial results, structuring and executing dozens of partnering transactions across  the product life cycle, raising debt and equity capital in the private and public markets totaling over $500  million, and working with founders, management teams, and boards to address complex business issues  to support their companies’ rapid growth. On the legal side, Matthew has extensive transactional and  general corporate experience, having served as the general counsel of several life science companies  including CareDx. 

Matt had strong entrepreneurial interests since he was a child. In high school, he started a travel  services business from his parent’s basement. Since then, has always enjoyed helping enterprises start  and grow. At Pfizer, Matt was the youngest in-house counsel hired and was exposed to senior level  executives and transactions as a junior attorney, which forced him to navigate the political and business  complexities of a Fortune 50 company with little professional experience. 

Matthew holds a B.A. degree in Government, cum laude and Phi Beta Kappa, from Cornell University  and a J.D. degree from the Villanova University School of Law.


2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
©Pharmaceutical & BioScience Society, International; Last Modified: 7/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
Submit a Text Ad